Literature DB >> 16140997

Multiplicity in polyp count and extracolonic manifestations in 40 Dutch patients with MYH associated polyposis coli (MAP).

M Nielsen, P F Franken, T H C M Reinards, M M Weiss, A Wagner, H van der Klift, S Kloosterman, J J Houwing-Duistermaat, C M Aalfs, M G E M Ausems, A H J T Bröcker-Vriends, E B Gomez Garcia, N Hoogerbrugge, F H Menko, R H Sijmons, S Verhoef, E J Kuipers, H Morreau, M H Breuning, C M J Tops, J T Wijnen, H F A Vasen, R Fodde, F J Hes.   

Abstract

OBJECTIVE: To investigate the contribution of MYH associated polyposis coli (MAP) among polyposis families in the Netherlands, and the prevalence of colonic and extracolonic manifestations in MAP patients.
METHODS: 170 patients with polyposis coli, who previously tested negative for APC mutations, were screened by denaturing gradient gel electrophoresis and direct sequencing to identify MYH germline mutations.
RESULTS: Homozygous and compound heterozygous MYH mutations were identified in 40 patients (24%). No difference was found in the percentage of biallelic mutation carriers between patients with 10-99 polyps or 100-1000 polyps (29% in both groups). Colorectal cancer was found in 26 of the 40 patients with MAP (65%) within the age range 21 to 67 years (median 45). Complete endoscopic reports were available for 16 MAP patients and revealed five cases with gastro-duodenal polyps (31%), one of whom also presented with a duodenal carcinoma. Breast cancer occurred in 18% of female MAP patients, significantly more than expected from national statistics (standardised morbidity ratio = 3.75).
CONCLUSIONS: Polyp numbers in MAP patients were equally associated with the attenuated and classical polyposis coli phenotypes. Two thirds of the MAP patients had colorectal cancer, 95% of whom were older than 35 years, and one third of a subset of patients had upper gastrointestinal lesions. Endoscopic screening of the whole intestine should be carried out every two years for all MAP patients, starting from age 25-30 years. The frequent occurrence of additional extraintestinal manifestations, such as breast cancer among female MAP patients, should be thoroughly investigated.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16140997      PMCID: PMC1736132          DOI: 10.1136/jmg.2005.033217

Source DB:  PubMed          Journal:  J Med Genet        ISSN: 0022-2593            Impact factor:   6.318


  59 in total

Review 1.  Biomarkers and molecular diagnosis of gastrointestinal and pancreatic neoplasms.

Authors:  Shelby D Melton; Robert M Genta; Rhonda F Souza
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2010-10-05       Impact factor: 46.802

2.  MUTYH associated polyposis coli: one common and one rare mutation.

Authors:  Heiko Ulrik De Schepper; Herbert Fierens; Piet-Hein Steger; Luc Colemont
Journal:  Dig Dis Sci       Date:  2012-03-09       Impact factor: 3.199

3.  Cancer risks for monoallelic MUTYH mutation carriers with a family history of colorectal cancer.

Authors:  Aung Ko Win; Sean P Cleary; James G Dowty; John A Baron; Joanne P Young; Daniel D Buchanan; Melissa C Southey; Terrilea Burnett; Patrick S Parfrey; Roger C Green; Loïc Le Marchand; Polly A Newcomb; Robert W Haile; Noralane M Lindor; John L Hopper; Steven Gallinger; Mark A Jenkins
Journal:  Int J Cancer       Date:  2011-04-08       Impact factor: 7.396

Review 4.  Lower gastrointestinal tract cancer predisposition syndromes.

Authors:  Neel B Shah; Noralane M Lindor
Journal:  Hematol Oncol Clin North Am       Date:  2010-12       Impact factor: 3.722

Review 5.  Repair of 8-oxoG:A mismatches by the MUTYH glycosylase: Mechanism, metals and medicine.

Authors:  Douglas M Banda; Nicole N Nuñez; Michael A Burnside; Katie M Bradshaw; Sheila S David
Journal:  Free Radic Biol Med       Date:  2017-01-10       Impact factor: 7.376

6.  Duodenal carcinoma in MUTYH-associated polyposis.

Authors:  M Nielsen; J W Poley; S Verhoef; M van Puijenbroek; M M Weiss; G T Burger; C J Dommering; H F A Vasen; E J Kuipers; A Wagner; H Morreau; F J Hes
Journal:  J Clin Pathol       Date:  2006-08-30       Impact factor: 3.411

7.  French experts report on MUTYH-associated polyposis (MAP).

Authors:  Bruno Buecher; Catherine Bonaïti; Marie-Pierre Buisine; Chrystelle Colas; Jean-Christophe Saurin
Journal:  Fam Cancer       Date:  2012-09       Impact factor: 2.375

8.  A complex rearrangement in the APC gene uncovered by multiplex ligation-dependent probe amplification.

Authors:  Constanze Pagenstecher; Dorothea Gadzicki; Dietlinde Stienen; Siegfried Uhlhaas; Elisabeth Mangold; Nils Rahner; Mine Arslan-Kirchner; Peter Propping; Waltraut Friedl; Stefan Aretz
Journal:  J Mol Diagn       Date:  2007-02       Impact factor: 5.568

9.  Immunohistochemistry is not an accurate first step towards the molecular diagnosis of MUTYH-associated polyposis.

Authors:  Rachel S van der Post; Carolien M Kets; Marjolijn J L Ligtenberg; Joannes H J M van Krieken; Nicoline Hoogerbrugge
Journal:  Virchows Arch       Date:  2008-11-25       Impact factor: 4.064

10.  Pathological features of colorectal carcinomas in MYH-associated polyposis.

Authors:  A M O'Shea; S P Cleary; M A Croitoru; H Kim; T Berk; N Monga; R H Riddell; A Pollett; S Gallinger
Journal:  Histopathology       Date:  2008-06-28       Impact factor: 5.087

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.